Healthcare Industry News: CoreValve
News Release - January 15, 2014
Medtronic to Appeal Federal District Court Verdict
MINNEAPOLIS - Jan. 15, 2014 -- (Healthcare Sales & Marketing Network) -- A jury in the Federal District Court of Delaware today decided in favor of Edwards Lifesciences, ruling that the Medtronic (MDT) CoreValve® System infringed on Edward`s Cribier patent (US Pat. No. 8,002,825). Medtronic intends to appeal.The jury found willful infringement and awarded Edwards total damages in the amount of $392.5 million. Medtronic anticipates U.S. regulatory approval of the CoreValve System for extreme risk patients by the end of its fiscal year 2014, and intends to begin selling the device in the U.S. at that time.
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic`s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Source: Medtronic
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
